Financials data is unavailable for this security.
Cash flow in DKKView more
In 2023, cash reserves at Scandion Oncology A/S fell by 51.09m. However, Cash Flow from Investing totalled 288.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 50.67m for operations while cash used for financing totalled 705.00k.
Cash flow per share | -0.3345 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.2014 |
---|---|
Tangible book value per share | 0.2014 |
More ▼
Balance sheet in DKKView more
Current ratio | 4.12 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0059 |
---|---|
Total debt/total capital | 0.0058 |
More ▼